MCM
QTTB icon

Monimus Capital Management’s Q32 Bio QTTB Stock Holding History

Monimus Capital Management’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$862K Buy
+134,310
New +$638K 0.24% 52

Other funds holding QTTB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Monimus Capital Management's QTTB Position: Q1 2026 in Review

Monimus Capital Management opened a new position in Q32 Bio (QTTB) in Q1 2026: 134,310 shares worth $862K. The stake represents 0.24% of the portfolio and ranks #52 among its holdings.

54 funds tracked by Wall St. Rank hold QTTB as of Q1 2026.

  • Monimus Capital Management held 134,310 shares of Q32 Bio worth $862K as of Q1 2026.
  • Q32 Bio was a new Monimus Capital Management position in Q1 2026.
  • Q32 Bio made up 0.24% of Monimus Capital Management's portfolio in Q1 2026, its #52 holding.
  • 54 funds tracked by Wall St. Rank held Q32 Bio as of Q1 2026.

Based on Monimus Capital Management's 13F filing for Q1 2026, filed 15 May 2026.